An update on the use of laser technology in skin vaccination

Expert Review of Vaccines

Volumn 12, Issue 11, 2013, Pages 1313-1323

  Chen, Xinyuan ^a   Wang, Ji ^a   Shah, Dilip ^a   Wu, Mei X ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

adjuvant; intradermal injection; laser; skin vaccination; stratum corneum; transcutaneous delivery; vaccine

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; AMINOLEVULINIC ACID; ASCORBIC ACID; BCG VACCINE; DNA VACCINE; FLUORESCEIN ISOTHIOCYANATE; FLUOROURACIL; HEPATITIS B SURFACE ANTIGEN; HYDROCORTISONE; IMIQUIMOD; INFLUENZA VACCINE; INSULIN; INTERFERON; METHOTREXATE; NARCOTIC ANALGESIC AGENT; NICOTINE VACCINE; OVALBUMIN; PEPTIDE HEN EGG LYSOZYME; PEPTIDE VACCINE; PR8 VACCINE; RABIES VACCINE; RECOMBINANT PHL 5WITH CPG; RHODAMINE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY TITER; ANTIGEN PRESENTING CELL; CELLULAR IMMUNITY; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; ERBIUM YAG LASER; HUMAN; ILLUMINATION; IMMUNOGENICITY; IMMUNOTHERAPY; LOW LEVEL LASER THERAPY; NARCOLEPSY; NEODYMIUM YAG LASER; NEUROLOGIC DISEASE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; TOBACCO DEPENDENCE; VACCINATION;

ADMINISTRATION, CUTANEOUS; HUMANS; LASER THERAPY, LOW-LEVEL; SKIN; VACCINATION; VACCINES;

EID: 84887386840     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.844070     Document Type: Review

References (96)

1. Schlipkoter U, Flahault A. Communicable diseases: Achievements and challenges for public health. Public Health Rev. 32, 90-119 (2010
2. Needham J (1999). Part 6, Medicine. In: Science and Civilization in China: Volume 6, Biology and Biological Technology. Cambridge University Press, Cambridge, UK 134 (2013
3. Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc.(Bayl. Univ Med. Cent.) 18(1), 21-25 (2005
4. Kim YC, Jarrahian C, Zehrung D, Mitragotri S, Prausnitz MR. Delivery systems for intradermal vaccination. Curr. Top. Microbiol. Immunol. 351, 77-112 (2012
5. Prausnitz MR, Langer R. Transdermal drug delivery. Nat. Biotechnol. 26(11), 1261-1268 (2008
6. Hamilton JG. Needle phobia: A neglected diagnosis. J. Fam. Pract. 41(2), 169-175 (1995
7. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: From immunology to clinical practice. Expert Rev. Vaccines 7(8), 1201-1214 (2008
8. Chen X, Wu MX. Laser vaccine adjuvant for cutaneous immunization. Expert Rev. Vaccines 10(10), 1397-1403 (2011
9. Combadiere B, Liard C. Transcutaneous and intradermal vaccination. Hum. Vaccin. 7(8), 811-827 (2011
10. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7(3), 179-190 (2007
11. Icardi G, Orsi A, Ceravolo A, Ansaldi F. Current evidence on intradermal influenza vaccines administered by Soluvia licensed micro injection system. Hum. Vaccin. Immunother. 8(1), 67-75 (2012
12. Laurent PE, Bonnet S, Alchas P et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 25(52), 8833-8842 (2007
13. Fox CB, Haensler J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev. Vaccines 12(7), 747-758 (2013
14. Mills DJ, Lau CL, Fearnley EJ, Weinstein P. The immunogenicity of a modified intradermal pre-exposure rabies vaccination schedule-A case series of 420 travelers. J. Travel. Med. 18(5), 327-332 (2011
15. Kothare SV, Wiznitzer M. Association between H1N1 vaccination and narcolepsycataplexy: Flu to sleep. Neurology 80(14), 1276-1277 (2013
16. Miller E, Andrews N, Stellitano L et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: Retrospective analysis. BMJ 346, f794 (2013
17. Nohynek H, Jokinen J, Partinen M et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoSOne 7(3), e33536 (2012
18. Oldstone MB. Molecular mimicry and immune-mediated diseases. FASEB J. 12(13), 1255-1265 (1998
19. Waisbren BA, Sr. Acquired autoimmunity after viral vaccination is caused by molecular mimicry and antigen complimentarity in the presence of an immunologic adjuvant and specific HLA patterns. Med. Hypotheses 70(2), 346-348 (2008
20. Spratt A, Key T, Vivian AJ. Chronic anterior uveitis following bacille Calmette-Guerin vaccination: Molecular mimicry in action? J. Pediatr. Ophthalmol. Strabismus 45(4), 252-253 (2008
21. Chen X, Pravetoni M, Bhayana B, Pentel PR, Wu MX. High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Vaccine 31(1), 159-164 (2012
22. Chen X, Kim P, Farinelli B et al. A novel laser vaccine adjuvant increases the motility of antigen presenting cells. PLoS. One 5(10), e13776 (2010
23. Nishibu A, Ward BR, Jester JV, Ploegh HL, Boes M, Takashima A. Behavioral responses of epidermal Langerhans cells in situ to local pathological stimuli. J. Invest Dermatol. 126(4), 787-796 (2006
24. Flacher V, Tripp CH, Stoitzner P et al. Epidermal Langerhans cells rapidly capture and present antigens from C-Type lectintargeting antibodies deposited in the dermis. J. Invest Dermatol. 130(3), 755-762 (2010
25. Liard C, Munier S, Joulin-Giet A et al. Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responses. J. Invest Dermatol. 132(3 Pt 1), 615-625 (2012
26. Ginhoux F, Tacke F, Angeli V et al. Langerhans cells arise from monocytes in vivo. Nat. Immunol. 7(3), 265-73 (2006
27. Sangaletti S, Gioiosa L, Guiducci C et al. Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. J. Cell Sci. 118(Pt 16), 3685-3694 (2005
28. Chen X, Zeng Q, Wu MX. Improved efficacy of dendritic cell-based immunotherapy by cutaneous laser illumination. Clin. Cancer Res. 18(8), 2240-2249 (2012
29. Pflicke H, Sixt M. Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels. J. Exp. Med. 206(13), 2925-2935 (2009
30. Cornuz J, Zwahlen S, Jungi WF et al. A vaccine against nicotine for smoking cessation: A randomized controlled trial. PLoS One 3(6), e2547 (2008
31. Hoogsteder PH, Kotz D, van Spiegel PI et al. The efficacy and safety of a nicotine conjugate vaccine (NicVAX(R)) or placebo co-Administered with varenicline (Champix (R)) for smoking cessation: Study protocol of a phase IIb, double blind, randomized, placebo controlled trial. BMC. Public Health 12, 1052 (2012
32. Chen X, Wu MX. How effective could laser-based approaches be in assisting dendritic cell immunotherapy? Immunotherapy 4(10), 983-985 (2012
33. Laubach HJ, Tannous Z, Anderson RR, Manstein D. Skin responses to fractional photothermolysis. Lasers Surg. Med. 38(2), 142-9 (2006
34. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: A new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg. Med. 34(5), 426-438 (2004
35. Lin JY, Warger WC, Izikson L, Anderson RR, Tannous Z. A prospective, randomized controlled trial on the efficacy of fractional photothermolysis on scar remodeling. Lasers Surg. Med. 43(4), 265-72 (2011
36. Saedi N, Petelin A, Zachary C. Fractionation: A new era in laser resurfacing. Clin. Plast. Surg. 38(3), 449-61, vii (2011
37. Waibel J, Wulkan AJ, Lupo M, Beer K, Anderson RR. Treatment of burn scars with the 1,550 nm nonablative fractional Erbium Laser. Lasers Surg. Med. 44(6), 441-446 (2012
38. Kool M, Soullie T, van Nimwegen M et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205(4), 869-882 (2008
39. Flach TL, Ng G, Hari A et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat. Med. 17(4), 479-487 (2011
40. Marichal T, Ohata K, Bedoret D et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat. Med. 17(8), 996-1002 (2011
41. Chen GY, Nunez G. Sterile inflammation: Sensing and reacting to damage. Nat. Rev. Immunol. 10(12), 826-837 (2010
42. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198), 1122-1126 (2008
43. Update on fractional laser technology. J. Clin. Aesthet. Dermatol. 3(1), 42-50 (2010
44. Brown AS. At-home laser and light-based devices. Curr. Probl. Dermatol. 42, 160-165 (2011
45. Zehrung D, Jarrahian C, Wales A. Intradermal delivery for vaccine dose sparing: Overview of current issues. Vaccine 31(34), 3392-3395 (2012
46. Sullivan SP, Koutsonanos DG, Del Pilar MM et al. Dissolving polymer microneedle patches for influenza vaccination. Nat. Med. 16(8), 915-920 (2010
47. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease. Clin. Rev. Allergy Immunol. 41(2), 163-168 (2011
48. Gherardi RK, Authier FJ. Macrophagic myofasciitis: Characterization and pathophysiology. Lupus 21(2), 184-189 (2012
49. Asa PB, Cao Y, Garry RF. Antibodies to squalene in Gulf War syndrome. Exp. Mol. Pathol. 68(1), 55-64 (2000
50. Tomljenovic L, Shaw CA. Do aluminum vaccine adjuvants contribute to the rising prevalence of autism? J. Inorg. Biochem. 105(11), 1489-1499 (2011
51. Phillips CJ, Matyas GR, Hansen CJ, Alving CR, Smith TC, Ryan MA. Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness. Vaccine 27(29), 3921-6 (2009
52. Guy B. The perfect mix recent progress in adjuvant research. Nat. Rev. Microbiol. 5(7), 505-517 (2007
53. Clapp T, Siebert P, Chen D, Jones BL. Vaccines with aluminum-containing adjuvants: Optimizing vaccine efficacy and thermal stability. J. Pharm. Sci. 100(2), 388-401 (2011
54. Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 30(13), 2256-2272 (2012
55. Collin N, Dubois PM. The Vaccine Formulation Laboratory: A platform for access to adjuvants. Vaccine 29(Suppl. 1) A37-A39 (2011
56. Glenn GM, Kenney RT, Ellingsworth LR, Frech SA, Hammond SA, Zoeteweij JP. Transcutaneous immunization and immunostimulant strategies: Capitalizing on the immunocompetence of the skin. Expert Rev. Vaccines 2(2), 253-267 (2003
57. Roukens AH, Vossen AC, Boland GJ, Verduyn W, van Dissel JT, Visser LG. Intradermal hepatitis B vaccination in non-responders after topical application of imiquimod (Aldara). Vaccine 28(26), 4288-4293 (2010
58. Othoro C, Johnston D, Lee R, Soverow J, Bystryn JC, Nardin E. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod. Infect. Immun. 77(2), 739-48 (2009
59. Johnston D, Bystryn JC. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine 24(11), 1958-1965 (2006
60. Scharton-Kersten T, Glenn GM, Vassell R, Yu J, Walwender D, Alving CR. Principles of transcutaneous immunization using cholera toxin as an adjuvant. Vaccine 17(Suppl. 2), S37-S43 (1999
61. Frerichs DM, Ellingsworth LR, Frech SA et al. Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. Vaccine 26(22), 2782-2787 (2008
62. Menon GK, Cleary GW, Lane ME. The structure and function of the stratum corneum. Int. J. Pharm. 435(1), 3-9 (2012
63. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv. Drug Deliv. Rev. 64(14), 1547-1568 (2012
64. Lee JW, Gadiraju P, Park JH, Allen MG, Prausnitz MR. Microsecond thermal ablation of skin for transdermal drug delivery. J. Control Release 154(1), 58-68 (2011
65. Polat BE, Hart D, Langer R, Blankschtein D. Ultrasound-mediated transdermal drug delivery: Mechanisms, scope, and emerging trends. J. Control Release 152(3), 330-348 (2011
66. Denet AR, Vanbever R, Preat V. Skin electroporation for transdermal and topical delivery. Adv. Drug Deliv. Rev. 56(5), 659-674 (2004
67. Nelson JS, McCullough JL, Glenn TC, Wright WH, Liaw LH, Jacques SL. Mid-infrared laser ablation of stratum corneum enhances in vitro percutaneous transport of drugs. J. Invest Dermatol. 97(5), 874-879 (1991
68. Lee WR, Pan TL, Wang PW, Zhuo RZ, Huang CM, Fang JY. Erbium:YAG laser enhances transdermal peptide delivery and skin vaccination. J. Control Release 128(3), 200-208 (2008
69. Wang KH, Fang JY, Hu CH, Lee WR. Erbium:YAG laser pretreatment accelerates the response of Bowen's disease treated by topical 5-fluorouracil. Dermatol. Surg. 30(3), 441-445 (2004
70. Fang JY, Lee WR, Shen SC, Fang YP, Hu CH. Enhancement of topical 5-Aminolaevulinic acid delivery by erbium: YAG laser and microdermabrasion: A comparison with iontophoresis and electroporation. Br. J. Dermatol.151(1), 132-140 (2004
71. Fang JY, Lee WR, Shen SC, Wang HY, Fang CL, Hu CH. Transdermal delivery of macromolecules by erbium:YAG laser. J. Control Release 100(1), 75-85 (2004
72. Lee WR, Shen SC, Liu CR, Fang CL, Hu CH, Fang JY. Erbium:YAG laser-mediated oligonucleotide and DNA delivery via the skin: An animal study. J. Control Release 115(3), 344-353 (2006
73. Lee WR, Shen SC, Fang CL, Liu CR, Fang JY. Skin pretreatment with an Er:YAG laser promotes the transdermal delivery of three narcotic analgesics. Lasers Med. Sci. 22(4), 271-278 (2007
74. Lee WR, Shen SC, Fang CL, Zhuo RZ, Fang JY. Topical delivery of methotrexate via skin pretreated with physical enhancement techniques: Low-fluence erbium:YAG laser and electroporation. Lasers Surg. Med. 40(7), 468-476 (2008
75. Lee WR, Shen SC, Zhuo RZ, Wang KC, Fang JY. Enhancement of topical small interfering RNA delivery and expression by low-fluence erbium:YAG laser pretreatment of skin. Hum. Gene Ther. 20(6), 580-588 (2009
76. Lee WR, Shen SC, Pai MH, Yang HH, Yuan CY, Fang JY. Fractional laser as a tool to enhance the skin permeation of 5-Aminolevulinic acid with minimal skin disruption: A comparison with conventional erbium:YAG laser. J. Control Release 145(2), 124-33 (2010
77. Chen X, Shah D, Kositratna G, Manstein D, Anderson RR, Wu MX. Facilitation of transcutaneous drug delivery and vaccine immunization by a safe laser technology. J. Control Release 159(1), 43-51 (2012
78. Haedersdal M, Sakamoto FH, Farinelli WA, Doukas AG, Tam J, Anderson RR. Fractional CO(2) laser-Assisted drug delivery. Lasers Surg. Med. 42(2), 113-122 (2010
79. Paasch U, Haedersdal M. Laser systems for ablative fractional resurfacing. Expert Rev. Med. Devices 8(1), 67-83 (2011
80. Tajirian AL, Goldberg DJ. Fractional ablative laser skin resurfacing: A review. J. Cosmet Laser Ther. 13(6), 262-264 (2011
81. Bloom BS, Brauer JA, Geronemus RG. Ablative fractional resurfacing in topical drug delivery: An update and outlook. Dermatol. Surg. 39(6), 839-848. (2013
82. Togsverd-BoK, HaakCS, Thaysen-Petersen D, Wulf HC, Anderson RR, Haedersdal M. Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: A randomized clinical trial.Br. J. Dermatol. 166(6), 1262-1269 (2012
83. Ruiz-Rodriguez R, Lopez L, Candelas D, Zelickson B. Enhanced efficacy of photodynamic therapy after fractional resurfacing: Fractional photodynamic rejuvenation. J. Drugs Dermatol. 6(8), 818-820 (2007
84. Lee WR, Shen SC, Al Suwayeh SA, Yang HH, Yuan CY, Fang JY. Laser-Assisted topical drug delivery by using a low-fluence fractional laser: Imiquimod and macromolecules. J. Control Release 153(3), 240-248 (2011
85. Weiss R, Hessenberger M, Kitzmuller S et al. Transcutaneous vaccination via laser microporation. J. Control Release 162(2), 391-399 (2012
86. Hessenberger M, Weiss R, Weinberger EE, Boehler C, Thalhamer J, Scheiblhofer S. Transcutaneous delivery of CpG-Adjuvanted allergen via laser-generated micropores. Vaccine 31(34), 3427-3434 (2012
87. Scheiblhofer S, Thalhamer J, Weiss R. Laser microporation of the skin: Prospects for painless application of protective and therapeutic vaccines. Expert Opin. Drug Deliv. 10(6), 761-773 (2013
88. Shangguan H, Casperson LW, Shearin A, Gregory KW, Prahl SA. Drug delivery with microsecond laser pulses into gelatin. Appl. Opt. 35(19), 3347-3357 (1996
89. Park MA, Jang HJ, Sirotkin FV, Yoh JJ. Er: YAG laser pulse for small-dose splashbackfree microjet transdermal drug delivery. Opt. Lett. 37(18), 3894-3896 (2012
90. Lee S, McAuliffe DJ, Flotte TJ, Kollias N, Doukas AG. Photomechanical transdermal delivery: The effect of laser confinement. Lasers Surg. Med. 28(4), 344-347 (2001
91. Kutzler MA, Weiner DB. DNA vaccines: Ready for prime time? Nat. Rev. Genet. 9(10), 776-788 (2008
92. Wang G, Pan L, Zhang Y. Approaches to improved targeting of DNA vaccines. Hum. Vaccin. 7(12), 1271-1281 (2011
93. Zeira E, Manevitch A, Manevitch Z et al. Femtosecond laser: A new intradermal DNA delivery method for efficient, long-Term gene expression and genetic immunization. FASEB J. 21(13), 3522-33 (2007
94. Tsen SW, Wu CY, Meneshian A, Pai SI, Hung CF, Wu TC. Femtosecond laser treatment enhances DNA transfection efficiency in vivo. J. Biomed. Sci. 16, 36 (2009
95. Chakravarty P, Qian W, El Sayed MA, Prausnitz MR. Delivery of molecules into cells using carbon nanoparticles activated by femtosecond laser pulses. Nat. Nanotechnol.; 5(8):607-611 (2010
96. Menezes V, Mathew Y, Takayama K, Kanno A, Hosseini H. Laser plasma jet driven microparticles for DNA/drug delivery. PLoS One 7(11), e50823 (2012